CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. These therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, are characterized by significant unmet medical need, and are seeing a shift towards high-value disease-modifying therapies and precision medicine approaches. The global neurological therapeutics market exceeds $138 billion ⁴, while the global oncology therapeutics market is projected to reach $400 billion ⁵ in the next decade. Neurology and oncology focused companies received nearly 50 percent of venture capital investments in therapeutics in 2025, and these were the most active therapeutic areas for business development transactions from 2022 to 2025, with oncology having 457 transactions and neurology 205 transactions, totaling over $100 billion ⁶ in value for both.

The company faces intense and rapidly evolving competition from major pharmaceutical and biotechnology companies, early-stage biotechnology companies, academic research institutions, and other public and private research organizations, many of which possess substantially greater financial, technical, manufacturing, marketing, and human resources. Key competitors in neurology include Biogen, UCB, Novartis, AbbVie, and Eisai, while in oncology, large, well-capitalized companies such as AstraZeneca, Bristol-Myers Squibb, Roche, Merck & Co., Pfizer, Eli Lilly, and Johnson & Johnson maintain extensive pipelines. The company also competes with firms like Roivant, Ligand Pharmaceuticals, and Fortress Biosciences in acquiring or in-licensing assets.

CNS Pharmaceuticals generates revenue through its core business model of identifying, acquiring, or in-licensing differentiated preclinical and clinical-stage assets in neurology and oncology, with a focus on novel, differentiated assets supported by strong biological rationale. The company's strategy prioritizes opportunities with near- to mid-term value inflection points, meaningful commercial potential, and relevance to its team's expertise, while maintaining capital discipline. As a development-stage biotechnology company, it has not generated any revenue from product sales and does not expect to do so unless and until it successfully completes development, obtains regulatory approval, and commercializes one or more drug candidates.

The company's prior development programs centered on two investigational compounds, TPI 287 and Berubicin. TPI 287 is an investigational chemotherapy agent of the abeotaxane class, designed to penetrate the blood-brain barrier and achieve therapeutic concentrations in the central nervous system. It has been evaluated in multiple early-phase clinical studies involving over 300 patients across several oncology indications, including glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma. A Phase 1/2 study of TPI 287 in combination with bevacizumab in recurrent glioblastoma patients showed an objective response rate of approximately 54% ⁷, including two complete responses, and a disease control rate of approximately 92% ⁸. The company obtained exclusive rights to TPI 287 intellectual property in the United States, Canada, Mexico, and Japan through an Exclusive License Agreement with Cortice Biosciences, Inc. in July 2024. Berubicin is an investigational anthracycline chemotherapy agent, which preclinical and early clinical studies suggest may penetrate the blood-brain barrier. A Phase 1 trial of Berubicin in recurrent malignant gliomas observed one complete response, one partial response, and several cases of stable disease among 25 evaluable patients, resulting in a disease control rate of approximately 44% ⁹. The company subsequently conducted a randomized Phase 2 superiority clinical trial (CNS-201) comparing Berubicin to lomustine in recurrent glioblastoma patients, which did not meet its primary endpoint of showing superiority in overall survival in March 2025. Both TPI 287 and Berubicin are currently being explored for out-licensing opportunities.

For the fiscal year ended December 31, 2025, CNS Pharmaceuticals reported a net loss of approximately $15,850,564 ¹⁰. Total operating expenses were approximately $15,986,559 ¹¹. General and administrative expenses were approximately $6,214,619 ¹², and research and development expenses were approximately $9,771,940 ¹³. The company had cash and cash equivalents of approximately $7,201,014 ¹⁴ as of December 31, 2025. Total current assets were $8,102,801 ¹⁵, and total current liabilities were $4,100,910 ¹⁶, resulting in a working capital of approximately $4,002,000 ¹⁷. Notes payable amounted to $328,571 ¹⁸. The accumulated deficit as of December 31, 2025, was $100,275,268 ¹⁹. Basic and diluted loss per share were both $(35.75) ²⁰. Net cash used in operating activities was approximately $13,811,107 ²¹.

Comparing the fiscal year ended December 31, 2025, to December 31, 2024, general and administrative expense increased from approximately $5,612,000 ²² in 2024 to $6,215,000 ²³ in 2025, primarily due to an increase of approximately $34,000 ²⁴ in professional expenses, $913,000 ²⁵ in employee compensation, $142,000 ²⁶ in travel expenses, $48,000 ²⁷ in insurance expenses, and other general and administrative expenses of $44,000 ²⁸, partially offset by a decrease of approximately $575,000 ²⁹ in stock-based compensation and $3,000 ³⁰ in board of director compensation. Research and development expense increased from approximately $9,290,000 ³¹ in 2024 to $9,772,000 ³² in 2025, mainly due to increased expenditures for preparing a TPI 287 trial, including drug manufacturing, offset by a decline in costs for the Berubicin trial. The net loss increased from approximately $14,858,000 ³³ in 2024 to $15,851,000 ³⁴ in 2025, primarily due to increased research and development costs. Net cash used in operating activities decreased from approximately $17,113,000 ³⁵ in 2024 to $13,811,000 ³⁶ in 2025. Net cash provided by financing activities decreased from approximately $23,030,000 ³⁷ in 2024 to $14,569,000 ³⁸ in 2025.

Significant operational developments during the period include the appointment of Rami Levin, MBA, as President & Chief Executive Officer on January 1, 2026, followed by the engagement of an independent life science advisory firm for a comprehensive strategic analysis. A new executive leadership team, including a Chief Business Officer, Chief Financial Officer, Chief Medical Officer, and Chief Technology Officer, was appointed effective March 2, 2026. On March 11, 2026, the company announced a new corporate growth strategy focused on building a high-value pipeline in neurology and oncology, pivoting from its historical singular focus on glioblastoma multiforme. As part of this pivot, the company intends to explore out-licensing opportunities for its legacy assets, TPI 287 and Berubicin. The company also terminated its license agreement with HPI on March 23, 2025.

CNS Pharmaceuticals estimates that its current cash on hand is sufficient to fund operations into the third quarter of 2026 ³⁹. The company's strategy is focused on identifying and securing the rights to development-stage assets in neurology and oncology and advancing any assets it obtains. However, the timing, cost, and ultimate success of these efforts are difficult to predict, and the company will require significant additional capital to advance any drug candidate. There are no commitments for such additional needed financing, and the company will likely need to raise capital through the sale of additional equity or debt securities.

A major growth area for CNS Pharmaceuticals is the strategic expansion into neurology and oncology through in-licensing or acquisition of new pipeline assets. The company is pursuing a disciplined approach to identify, acquire, or in-license differentiated preclinical and clinical-stage assets with strong biological rationale, validated or emerging clinical data, and clear development and regulatory pathways. The focus is on opportunities with near- to mid-term value inflection points, meaningful commercial potential, and relevance to the executive team's expertise, while maintaining capital discipline. A global asset search has been initiated, actively evaluating opportunities aligned with these criteria, particularly in areas with strong investor interest, partnering activity, and long-term value creation potential.

The company's operational outlook includes a focus on deploying capital efficiently and with discipline, leveraging its team's experience to advance assets across their lifecycles. This involves a holistic assessment of each program, including development timelines, capital requirements, and probability-weighted outcomes. The company intends to pursue development strategies and regulatory pathways designed to generate high-quality data to support clinical advancement, informed decision-making, and, if successful, regulatory submissions for product approval. The company also plans to transform its operations and execution, building its team, systems, and capabilities in a stage-appropriate manner to support future growth as its pipeline builds and advances.

Regarding capital allocation, the company has historically funded its operations primarily through the sale of equity securities in public and private offerings. It expects to continue funding operations through equity financings, debt financings, collaborations, strategic alliances, licensing arrangements, or other available capital sources. The company's primary working capital needs are related to business development activities for identifying, evaluating, and securing funding for research and development, including payments to contract research organizations, contract manufacturing organizations, and other third-party service providers, as well as general and administrative expenses for operating as a public company. The company has never declared or paid any cash dividends and currently intends to retain any future earnings to finance business growth and development.

Management has explicitly flagged several structural headwinds and execution risks to its growth plan. The company's future success is highly dependent on its ability to identify, acquire, or license new drug candidates, which may not be successful due to intense competition and the greater resources of competitors. Any acquired or licensed drug candidates will likely require significant additional development and may not prove safe, effective, or commercially viable. The company may not have access to sufficient capital to pursue acquisition or licensing opportunities, which could limit pipeline expansion. Furthermore, the company will require substantial funding to execute its new corporate strategy, which may not be available on acceptable terms, or at all, potentially leading to delays, limitations, reductions, or cessation of operations. The company's ability to out-license its legacy assets, TPI 287 and Berubicin, is uncertain, and potential licensors may require additional preclinical or clinical data, CMC data, or intellectual property considerations that may not be feasible or cost-prohibitive, potentially leading to the sunsetting of these programs.

CNS Pharmaceuticals faces material risks across several domains. Operationally, the company has a limited operating history and has never been profitable, incurring an accumulated deficit of $100,275,268 ¹⁹ as of December 31, 2025. Its ability to continue as a going concern is dependent on obtaining future equity financings, as indicated by its auditors. The company relies heavily on third-party manufacturers for API production and contract research organizations for clinical trials, exposing it to risks of supply chain disruptions, manufacturing non-compliance with cGMP regulations, and potential product liability claims. Cybersecurity risks are present due to reliance on information technology and third-party SaaS providers, with potential for operational failures, data breaches, and significant financial damages. The company's intellectual property for TPI 287 will expire in 2028 ⁴⁰, and while Berubicin has Orphan Drug Designation (ODD) which may provide 7 years ⁴¹ of market exclusivity from NDA approval, ODD does not bar approval of clinically superior or market-demand-meeting products. The company has identified material weaknesses in internal controls over financial reporting as of December 31, 2025, due to a lack of segregation of duties, limited access to timely and complete information from its CRO, and insufficient formal documentation of its control environment. Financially, the company's cash balances may exceed the FDIC insurance limit of $250,000 ⁴² from time to time, with $6,445,843 ⁴³ in excess as of December 31, 2025, exposing it to risks from financial institution failures. The company is also subject to intense and rapidly evolving competition in the biotechnology and pharmaceutical industries, with many competitors possessing greater financial and other resources.

Management's overall tone emphasizes a decisive strategic pivot to reposition the company for long-term success, focusing on building a high-value pipeline in neurology and oncology. This new corporate growth strategy, announced on March 11, 2026, follows a comprehensive, data-driven strategic review. The company has assembled a new executive leadership team, including Rami Levin as President & CEO, Lynne Kelley as Chief Medical Officer, Dylan Wenke as Chief Business Officer, Steve O’Loughlin as Chief Financial Officer, and Eric Faulkner as Chief Technology Officer, all appointed in early 2026, to execute this strategy. Key strategic priorities include identifying, evaluating, and selecting novel, differentiated assets with best-in-class potential, supported by strong biological rationale and clear development and regulatory pathways; being data-driven in decision-making to de-risk development and prioritize programs with clear clinical inflection points; deploying capital efficiently and with discipline, leveraging the team's experience for holistic program assessment; focusing on patient-centered development addressing serious unmet medical needs in neurology (disease modification) and oncology (overall survival, durability of response, quality of life); and transforming every aspect of CNS Pharmaceuticals, including building the team, systems, and capabilities to support future growth. The company explicitly states its intention to explore out-licensing opportunities for its legacy assets, TPI 287 and Berubicin, as they are not in line with the new strategic direction. Management estimates that current capital is sufficient to fund operations into the third quarter of 2026 ³⁹, but acknowledges the need to raise significant additional capital in the future.